Ansuvimab is indicated for the treatment of infection caused by Zaire ebolavirus in adults and kids, including newborns of mothers who are RT-PCR positive for Zaire ebolavirus infection.
Ansuvimab is a monoclonal antibody prescribed for treating Zaire ebolavirus infection. This virus can change over time and there is high chance of emergence of resistance.
• Allergic to Ansuvimab
• Children aged below 18 years
• Adults aged above 65 years
It is available as injection: 400 mg lyophilized powder in a single-dose vial for reconstitution and further dilution. Dose should be calculated based on the patient’s actual weight in kg.
The recommended dose is 50 mg/kg reconstituted. It is administered as a single intravenous infusion over 60 minutes.
It should be reconstituted with sterile water for injection, then further diluted in 0.9% Sodium Chloride injection. Before reconstitution, allow the vial to reach ambient temperature (15°C to 27°C [59°F to 81°F]) for 20 minutes.
The diluted IV solution can be infused via a central line or peripheral catheter. It should not be given as an IV push or bolus.
• General: Fever, chills
• Cardiovascular:-ore heart rate Rapid heartbeat (Tachycardia), Low blood pressure
• Gastrointestinal: Diarrhea, Vomiting
• Respiratory system: Increased respiratory rate
• Ansuvimab may cause allergic reactions including infusion-related events, which may be acute, life-threatening reactions during and after the infusion. In case of severe or life-threatening hypersensitivity reactions, discontinue the administration immediately and seek appropriate emergency care.
• Patients infected with Zaire ebolavirus should not breastfed.
Do not take Ansuvimab with: • Live vaccines
Store Ansuvimab injection in ambient temperature (15°C to 27°) or in the refrigerator at 2 to 8oC It should be protected from light